| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 21 | 2020 | 201 | 6.550 |
Why?
|
| Hypoglycemic Agents | 12 | 2021 | 57 | 3.230 |
Why?
|
| Insulin | 11 | 2021 | 92 | 3.180 |
Why?
|
| Pancreatitis | 4 | 2021 | 25 | 2.490 |
Why?
|
| Blood Glucose | 10 | 2021 | 112 | 2.210 |
Why?
|
| Hypertriglyceridemia | 3 | 2021 | 20 | 2.040 |
Why?
|
| Hyperglycemia | 6 | 2021 | 34 | 2.030 |
Why?
|
| Diabetes Mellitus | 5 | 2021 | 140 | 1.820 |
Why?
|
| Hyperaldosteronism | 3 | 2020 | 3 | 1.420 |
Why?
|
| Middle Aged | 38 | 2022 | 9953 | 1.320 |
Why?
|
| Diabetic Nephropathies | 2 | 2018 | 28 | 1.160 |
Why?
|
| Triglycerides | 3 | 2021 | 45 | 1.110 |
Why?
|
| Male | 43 | 2022 | 15879 | 1.100 |
Why?
|
| Female | 44 | 2022 | 16438 | 1.070 |
Why?
|
| Glucocorticoids | 2 | 2021 | 69 | 1.060 |
Why?
|
| Adult | 32 | 2022 | 8731 | 1.040 |
Why?
|
| Patient Care Team | 2 | 2018 | 141 | 1.030 |
Why?
|
| Humans | 65 | 2022 | 29856 | 1.010 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 158 | 1.010 |
Why?
|
| Poverty | 4 | 2019 | 97 | 1.000 |
Why?
|
| Adenoma | 3 | 2020 | 41 | 0.960 |
Why?
|
| Life Style | 2 | 2017 | 212 | 0.930 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 97 | 0.920 |
Why?
|
| Hyperthyroidism | 2 | 2022 | 11 | 0.910 |
Why?
|
| Thyroxine | 2 | 2022 | 25 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2019 | 194 | 0.840 |
Why?
|
| Pituitary Neoplasms | 3 | 2014 | 20 | 0.830 |
Why?
|
| Retrospective Studies | 12 | 2022 | 3325 | 0.830 |
Why?
|
| Insulin-Secreting Cells | 2 | 2020 | 6 | 0.800 |
Why?
|
| Urban Population | 3 | 2019 | 143 | 0.790 |
Why?
|
| Thyroid Neoplasms | 7 | 2013 | 38 | 0.770 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 1 | 0.740 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 77 | 0.710 |
Why?
|
| Metformin | 2 | 2020 | 23 | 0.710 |
Why?
|
| Prednisone | 1 | 2020 | 68 | 0.700 |
Why?
|
| Kidney | 2 | 2019 | 176 | 0.650 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 54 | 0.640 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 161 | 0.630 |
Why?
|
| Gallstones | 1 | 2018 | 6 | 0.610 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 28 | 0.610 |
Why?
|
| Secondary Prevention | 1 | 2018 | 63 | 0.600 |
Why?
|
| Insulin Resistance | 6 | 2020 | 60 | 0.600 |
Why?
|
| Minority Groups | 1 | 2018 | 67 | 0.590 |
Why?
|
| Risk Factors | 12 | 2019 | 2466 | 0.590 |
Why?
|
| Aged | 20 | 2021 | 9654 | 0.580 |
Why?
|
| Dipeptides | 1 | 2016 | 4 | 0.550 |
Why?
|
| Adamantane | 1 | 2016 | 2 | 0.550 |
Why?
|
| Self-Management | 3 | 2020 | 13 | 0.490 |
Why?
|
| Safety-net Providers | 1 | 2014 | 8 | 0.480 |
Why?
|
| Health Education | 1 | 2014 | 41 | 0.470 |
Why?
|
| Health Behavior | 4 | 2019 | 159 | 0.460 |
Why?
|
| Minority Health | 1 | 2013 | 2 | 0.460 |
Why?
|
| Urban Health | 1 | 2013 | 23 | 0.460 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 232 | 0.450 |
Why?
|
| Chicago | 4 | 2021 | 867 | 0.440 |
Why?
|
| Alcoholism | 1 | 2013 | 83 | 0.430 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 970 | 0.430 |
Why?
|
| Diabetes Complications | 3 | 2016 | 64 | 0.430 |
Why?
|
| Obesity | 3 | 2013 | 289 | 0.430 |
Why?
|
| Pharmacists | 1 | 2012 | 16 | 0.410 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 28 | 0.410 |
Why?
|
| Ambulatory Care | 1 | 2012 | 78 | 0.400 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 1859 | 0.390 |
Why?
|
| Eating | 1 | 2011 | 46 | 0.380 |
Why?
|
| Patient Discharge | 1 | 2012 | 151 | 0.380 |
Why?
|
| Acromegaly | 2 | 2020 | 3 | 0.360 |
Why?
|
| Hexoses | 1 | 2010 | 2 | 0.350 |
Why?
|
| Exercise | 4 | 2019 | 474 | 0.350 |
Why?
|
| Aldosterone | 2 | 2020 | 3 | 0.350 |
Why?
|
| Sweetening Agents | 1 | 2010 | 7 | 0.350 |
Why?
|
| Leuprolide | 1 | 2010 | 3 | 0.350 |
Why?
|
| Glipizide | 1 | 2009 | 1 | 0.350 |
Why?
|
| Young Adult | 5 | 2020 | 1966 | 0.340 |
Why?
|
| Body Mass Index | 4 | 2017 | 425 | 0.340 |
Why?
|
| Adrenal Insufficiency | 1 | 2009 | 7 | 0.330 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2009 | 9 | 0.330 |
Why?
|
| Acute Disease | 4 | 2019 | 225 | 0.330 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2002 | 16 | 0.330 |
Why?
|
| Disease Progression | 4 | 2019 | 812 | 0.310 |
Why?
|
| Brain Diseases | 1 | 2009 | 83 | 0.310 |
Why?
|
| Prevalence | 4 | 2018 | 494 | 0.310 |
Why?
|
| Inpatients | 2 | 2012 | 141 | 0.300 |
Why?
|
| Community Health Workers | 1 | 2008 | 29 | 0.300 |
Why?
|
| Primary Health Care | 1 | 2008 | 95 | 0.280 |
Why?
|
| Carcinoma, Papillary | 3 | 2002 | 20 | 0.270 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 376 | 0.270 |
Why?
|
| Prediabetic State | 1 | 2006 | 4 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 18 | 0.270 |
Why?
|
| Stroke | 1 | 2010 | 294 | 0.270 |
Why?
|
| Medication Adherence | 2 | 2020 | 79 | 0.270 |
Why?
|
| Ketone Bodies | 1 | 2005 | 5 | 0.260 |
Why?
|
| Incidence | 3 | 2018 | 759 | 0.250 |
Why?
|
| Hospitals, Public | 2 | 2016 | 31 | 0.250 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 67 | 0.250 |
Why?
|
| Adolescent | 5 | 2014 | 2331 | 0.250 |
Why?
|
| Sex Factors | 3 | 2017 | 497 | 0.240 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 329 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1462 | 0.240 |
Why?
|
| Thyroglobulin | 4 | 1992 | 5 | 0.240 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2020 | 4 | 0.240 |
Why?
|
| Thyrotropin | 2 | 2022 | 11 | 0.240 |
Why?
|
| Research Design | 2 | 2017 | 214 | 0.230 |
Why?
|
| Health Literacy | 2 | 2017 | 105 | 0.230 |
Why?
|
| Somatostatin | 2 | 2020 | 5 | 0.230 |
Why?
|
| Octreotide | 2 | 2020 | 7 | 0.230 |
Why?
|
| Peptides, Cyclic | 2 | 2020 | 13 | 0.230 |
Why?
|
| United States | 4 | 2020 | 2344 | 0.220 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1126 | 0.210 |
Why?
|
| Age Factors | 4 | 2018 | 852 | 0.210 |
Why?
|
| Tachycardia, Sinus | 1 | 2022 | 2 | 0.210 |
Why?
|
| Tachycardia | 1 | 2022 | 53 | 0.210 |
Why?
|
| Thyroid Gland | 5 | 1992 | 26 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2017 | 251 | 0.190 |
Why?
|
| Mineralocorticoids | 1 | 2020 | 1 | 0.180 |
Why?
|
| Adrenal Glands | 1 | 2020 | 8 | 0.180 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| C-Peptide | 1 | 2020 | 7 | 0.180 |
Why?
|
| Insulin, Long-Acting | 2 | 2010 | 2 | 0.180 |
Why?
|
| Thirst | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hypernatremia | 1 | 2019 | 2 | 0.170 |
Why?
|
| Single-Blind Method | 1 | 2019 | 120 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2014 | 1820 | 0.160 |
Why?
|
| Depressive Disorder | 1 | 2019 | 191 | 0.160 |
Why?
|
| Case-Control Studies | 1 | 2020 | 640 | 0.160 |
Why?
|
| Hypertension | 3 | 2011 | 272 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 297 | 0.150 |
Why?
|
| Age of Onset | 2 | 2016 | 108 | 0.140 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1997 | 2 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 286 | 0.140 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 12 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 12 | 0.140 |
Why?
|
| Patient Dropouts | 1 | 2016 | 28 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3557 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 59 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 384 | 0.140 |
Why?
|
| Self Efficacy | 1 | 2017 | 57 | 0.140 |
Why?
|
| Energy Intake | 1 | 2017 | 66 | 0.140 |
Why?
|
| Point Mutation | 1 | 1996 | 30 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 191 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2011 | 683 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 346 | 0.130 |
Why?
|
| Receptors, Dopamine | 2 | 2014 | 30 | 0.130 |
Why?
|
| Depression | 2 | 2017 | 472 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 245 | 0.130 |
Why?
|
| Liver | 2 | 2010 | 175 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1996 | 91 | 0.130 |
Why?
|
| Cultural Competency | 1 | 2014 | 8 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1185 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 411 | 0.120 |
Why?
|
| Counseling | 1 | 2014 | 47 | 0.120 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 2 | 0.120 |
Why?
|
| Accelerometry | 1 | 2014 | 87 | 0.120 |
Why?
|
| Self Care | 1 | 2014 | 90 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2014 | 99 | 0.110 |
Why?
|
| SEER Program | 1 | 2013 | 38 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 95 | 0.110 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 47 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 87 | 0.110 |
Why?
|
| Carcinoma | 1 | 2013 | 59 | 0.110 |
Why?
|
| Social Support | 1 | 2014 | 186 | 0.110 |
Why?
|
| Diet | 1 | 2014 | 172 | 0.110 |
Why?
|
| Health Promotion | 1 | 2014 | 162 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2019 | 1953 | 0.100 |
Why?
|
| Algorithms | 2 | 2005 | 400 | 0.100 |
Why?
|
| Iodoproteins | 1 | 1992 | 1 | 0.100 |
Why?
|
| Goiter | 1 | 1992 | 2 | 0.100 |
Why?
|
| Outpatients | 1 | 2012 | 54 | 0.100 |
Why?
|
| Poverty Areas | 1 | 2011 | 9 | 0.100 |
Why?
|
| Injections | 1 | 2011 | 57 | 0.100 |
Why?
|
| Albuminuria | 1 | 2011 | 21 | 0.100 |
Why?
|
| Thyroid Diseases | 2 | 2002 | 13 | 0.100 |
Why?
|
| Hypoglycemia | 2 | 2010 | 14 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 676 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 143 | 0.090 |
Why?
|
| Gilbert Disease | 1 | 1990 | 1 | 0.090 |
Why?
|
| Glycogen Storage Disease Type VII | 1 | 1990 | 1 | 0.090 |
Why?
|
| Hyperbilirubinemia, Hereditary | 1 | 1990 | 1 | 0.090 |
Why?
|
| Glycogen Storage Disease | 1 | 1990 | 2 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 12 | 0.090 |
Why?
|
| Insulin Detemir | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glycogenolysis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Insulin Lispro | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glycosides | 1 | 1990 | 2 | 0.090 |
Why?
|
| Chondroitin | 1 | 1990 | 6 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2010 | 56 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 3 | 0.090 |
Why?
|
| Diastole | 1 | 2010 | 36 | 0.090 |
Why?
|
| Sella Turcica | 1 | 2010 | 5 | 0.090 |
Why?
|
| Chondroitin Sulfates | 1 | 1990 | 30 | 0.090 |
Why?
|
| Insulin Glargine | 1 | 2009 | 1 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 31 | 0.090 |
Why?
|
| Hypothyroidism | 2 | 2005 | 32 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 133 | 0.080 |
Why?
|
| Radiotherapy | 1 | 1989 | 53 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 455 | 0.080 |
Why?
|
| Spinal Cord Compression | 1 | 2009 | 31 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2008 | 11 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2009 | 48 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 110 | 0.080 |
Why?
|
| Comorbidity | 2 | 2008 | 504 | 0.080 |
Why?
|
| Community Health Services | 1 | 2008 | 31 | 0.080 |
Why?
|
| Time Factors | 2 | 2009 | 1640 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 1989 | 194 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 33 | 0.070 |
Why?
|
| Knowledge | 1 | 2007 | 19 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 36 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1986 | 6 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1986 | 9 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2008 | 402 | 0.070 |
Why?
|
| Animals | 5 | 2010 | 4653 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 2 | 0.070 |
Why?
|
| Hyperinsulinism | 1 | 2006 | 4 | 0.070 |
Why?
|
| Goiter, Substernal | 1 | 1986 | 1 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 1986 | 50 | 0.070 |
Why?
|
| Choristoma | 1 | 1986 | 8 | 0.070 |
Why?
|
| Thoracic Neoplasms | 1 | 1986 | 9 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 1986 | 59 | 0.070 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1985 | 3 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 30 | 0.060 |
Why?
|
| Medical Record Linkage | 1 | 2005 | 5 | 0.060 |
Why?
|
| Thyroid Function Tests | 1 | 2005 | 8 | 0.060 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2005 | 18 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2005 | 53 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 21 | 0.060 |
Why?
|
| Gluconeogenesis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2003 | 11 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 22 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2003 | 39 | 0.050 |
Why?
|
| Pleural Diseases | 1 | 1983 | 2 | 0.050 |
Why?
|
| Fistula | 1 | 1983 | 4 | 0.050 |
Why?
|
| Renal Artery | 1 | 1983 | 6 | 0.050 |
Why?
|
| Colonic Diseases | 1 | 1983 | 12 | 0.050 |
Why?
|
| Hematuria | 1 | 1983 | 15 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 1986 | 352 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2003 | 53 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1985 | 203 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 1983 | 32 | 0.050 |
Why?
|
| Diarrhea | 1 | 1983 | 47 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 8 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 11 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 32 | 0.050 |
Why?
|
| Heart Block | 1 | 1982 | 19 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 125 | 0.050 |
Why?
|
| Bradycardia | 1 | 1982 | 29 | 0.050 |
Why?
|
| Celiac Disease | 1 | 1981 | 9 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 1983 | 117 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2004 | 312 | 0.050 |
Why?
|
| Patient Selection | 1 | 2003 | 234 | 0.050 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1992 | 12 | 0.050 |
Why?
|
| Sulfates | 2 | 1991 | 16 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 334 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 1992 | 16 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 12 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 10 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 35 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 38 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 51 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 78 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2019 | 3 | 0.040 |
Why?
|
| Bromocriptine | 1 | 2019 | 15 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2019 | 30 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 48 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1980 | 175 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 130 | 0.040 |
Why?
|
| Thyroidectomy | 2 | 1989 | 11 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 103 | 0.040 |
Why?
|
| Base Sequence | 2 | 1996 | 131 | 0.040 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2020 | 106 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 113 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 241 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 64 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 86 | 0.040 |
Why?
|
| Reference Values | 2 | 1996 | 230 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 802 | 0.040 |
Why?
|
| Nervous System Neoplasms | 1 | 1997 | 3 | 0.040 |
Why?
|
| Hyperparathyroidism | 1 | 1997 | 7 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1997 | 15 | 0.040 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 7 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 5 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 6 | 0.030 |
Why?
|
| Recurrence | 2 | 1989 | 352 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 2 | 1991 | 8 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1994 | 6 | 0.030 |
Why?
|
| Testis | 1 | 1994 | 12 | 0.030 |
Why?
|
| Primates | 1 | 1994 | 17 | 0.030 |
Why?
|
| Histones | 1 | 1994 | 28 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 251 | 0.030 |
Why?
|
| Antibodies | 2 | 1983 | 66 | 0.030 |
Why?
|
| Child | 1 | 1996 | 1376 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1992 | 4 | 0.030 |
Why?
|
| Immune Sera | 1 | 1992 | 9 | 0.030 |
Why?
|
| Amino Acids | 1 | 1992 | 21 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 35 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1992 | 26 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1992 | 44 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1992 | 24 | 0.020 |
Why?
|
| Carbohydrates | 1 | 1991 | 14 | 0.020 |
Why?
|
| Phosphates | 1 | 1991 | 21 | 0.020 |
Why?
|
| Rats | 2 | 1992 | 875 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 267 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 778 | 0.020 |
Why?
|
| Pedigree | 1 | 1990 | 65 | 0.020 |
Why?
|
| Galactose | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chondroitin Lyases | 1 | 1990 | 6 | 0.020 |
Why?
|
| Muscles | 1 | 1990 | 73 | 0.020 |
Why?
|
| Electromyography | 1 | 1990 | 79 | 0.020 |
Why?
|
| Pericardium | 1 | 2010 | 20 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2010 | 61 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 42 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 1989 | 2 | 0.020 |
Why?
|
| Biopsy | 1 | 1990 | 239 | 0.020 |
Why?
|
| Exercise Test | 1 | 1990 | 123 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 298 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 1989 | 13 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2008 | 27 | 0.020 |
Why?
|
| Smoking | 1 | 2008 | 194 | 0.020 |
Why?
|
| Mice | 1 | 1992 | 1647 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 372 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1986 | 43 | 0.020 |
Why?
|
| Bartter Syndrome | 1 | 1986 | 2 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1986 | 55 | 0.020 |
Why?
|
| Pharmacies | 1 | 2005 | 2 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2005 | 3 | 0.020 |
Why?
|
| Laboratories | 1 | 2005 | 26 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 40 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 97 | 0.020 |
Why?
|
| Polysomnography | 1 | 2005 | 94 | 0.020 |
Why?
|
| Butyrophenones | 1 | 1983 | 1 | 0.010 |
Why?
|
| Spiperone | 1 | 1983 | 3 | 0.010 |
Why?
|
| Arteries | 1 | 2003 | 17 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1983 | 4 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2003 | 46 | 0.010 |
Why?
|
| Kidney Calculi | 1 | 1983 | 4 | 0.010 |
Why?
|
| Drinking | 1 | 1983 | 5 | 0.010 |
Why?
|
| Radioactive Hazard Release | 1 | 2002 | 1 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1983 | 61 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2002 | 9 | 0.010 |
Why?
|
| Abscess | 1 | 1983 | 26 | 0.010 |
Why?
|
| Unconsciousness | 1 | 1982 | 8 | 0.010 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1981 | 2 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2005 | 283 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 414 | 0.010 |
Why?
|
| Anions | 2 | 1991 | 8 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1991 | 37 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1982 | 219 | 0.010 |
Why?
|
| Radiography | 1 | 1983 | 678 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1980 | 90 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 542 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 654 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1980 | 94 | 0.010 |
Why?
|
| Echocardiography | 1 | 1980 | 173 | 0.010 |
Why?
|
| Calcium | 1 | 2003 | 496 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 874 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 15 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1994 | 22 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1994 | 38 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 33 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 45 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1994 | 49 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 191 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 163 | 0.010 |
Why?
|
| Rabbits | 2 | 1983 | 283 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1991 | 1 | 0.010 |
Why?
|
| Sialic Acids | 1 | 1991 | 1 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 10 | 0.010 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 1991 | 4 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1991 | 18 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 1991 | 18 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 149 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1986 | 7 | 0.000 |
Why?
|
| Indomethacin | 1 | 1986 | 8 | 0.000 |
Why?
|
| Renin-Angiotensin System | 1 | 1986 | 7 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1983 | 8 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1983 | 54 | 0.000 |
Why?
|
| Cattle | 1 | 1983 | 217 | 0.000 |
Why?
|
| Benzodiazepinones | 1 | 1983 | 2 | 0.000 |
Why?
|
| Antibody Affinity | 1 | 1983 | 3 | 0.000 |
Why?
|
| Flunitrazepam | 1 | 1983 | 2 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1983 | 15 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1983 | 113 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1983 | 38 | 0.000 |
Why?
|